Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by various company officers on July 9, 2011, through the Company's Share Reward Plan. The purchase price was 1369.704 pence per Ordinary share. Specific acquisitions included:
- Mr A P Witty: 31 shares
- Mr S M Bicknell: 31 shares
- Mr E J Gray: 31 shares
- Mr S A Hussain: 7 shares
- Dr D Pulman: 11 shares
- Mr D S Redfern: 31 shares
- Ms C Thomas: 31 shares
- Mr P C Thomson: 12 shares
- Dr P J T Vallance: 14 shares
- Mrs V A Whyte: 25 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of share purchases in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1369.704 pence against market data for July 9, 2011.
- Confirm the total number of shares acquired by insiders under the Dividend Reinvestment element of the Plan.
- Review the company's annual report (Form 20-F) for comprehensive financial metrics not included in this transaction notification.